A Chinese venture capital firm with offices in Shanghai and Beijing has raised two funds to date, with its second fund raised in 2011 at USD 125 million. The firm mainly invests in early stage high-growth technology businesses but has expanded its interest into medical technology. The firm generally allocates USD 5-10 million per company, and focuses 70% domestically and 30% on the US. The firm is interested in companies that have a China angle, specifically, developing products relevant to the Chinese market. The firm is actively seeking new investment opportunities.
In healthcare, the firm is currently looking for medical devices that address a large market in China. IVD and devices with a software component are of high interest. The firm is opportunistic in terms of subsectors and considers all classes of devices. In terms of the stage of development, the firm prefers devices that have regulatory approval (preferably CE mark); ideally, the device should be ready for CFDA. However, the firm will also consider devices in the final stages of clinical trials.
The firm can invest globally but the firm is only interested in companies that have a China angle, i.e. Chinese-led and/or developing products for the Chinese market. The firm has no revenue requirements.
If you are interested in more information about this investor and other investors tracked by LSN, please emailĀ mandates@lifesciencenation.com
An early-stage healthcare technology venture capital investment firm based in Boston, Massachusetts recently raised $200 million for its first dedicated healthcare technology-focused fund in 2015. The firm primarily invests in companies in the seed, series A and B stages targeting healthcare technology and services and is seeking 8-10 new investments within the next year. The firm typically invests an initial range of $500K-$5M and may go up to investing $10M-$15M per company overall, though the size may vary depending on the opportunity. The firm primarily invests in companies based in the US, though is open to companies on a global level. The firm seeks to be a significant investor in any of its portfolio companies and will often serve on the boards of those companies.
In the healthcare technology sector, the firm is actively seeking new investments in healthcare software and services sectors with a specific focus on healthcare analytics, healthcare infrastructure, and novel service delivery models. The firm has a specific interest in transformational technologies and services that enable value-based healthcare and leverage wireless, data and analytics technologies. The firm currently is not focused on therapeutics or medical device investment opportunities, though has interest in medical devices with a software/data component, such as sensors. The firm may be open to 510K devices, however, it is not interested in PMA devices. The firm is indication agnostic and invests only in pre-revenue early stage products.
The firm seeks to invest in privately held companies with a strong and experience management team. The group prefers to invest in companies with cutting-edge technologies and large market potential.
If you are interested in more information about this investor and other investors tracked by LSN, please emailĀ mandates@lifesciencenation.com
A firm based in California with additional offices throughout the USA and Asia invests broadly in the healthcare and technology sectors, in both venture and growth-stage financing rounds. The firm has a large fund that invests only in rounds that raise $10 million or more. The firm makes investments globally.
Within healthcare, the firm focuses on biopharma, and also invests in medical devices, healthcare IT and healthcare service providers. The firm is not currently seeking opportunities in diagnostics. In biopharma, the firm prefers to invest in companies that have obtained data from human clinical trials; however, the firm also invests in breakthrough therapeutic technologies at the preclinical stage. In medical devices, the firm only invests in growth-stage companies with an approved product and initial revenues; the firm prefers to invest in breakthrough device technologies and avoids commodity markets. The firm has a broad portfolio and is open to any indication area, but has a particular focus in oncology and orphan diseases, and typically does not invest in infectious diseases.
Within the service provision and IT sectors, the firm is focused on opportunities that provide cost savings to the healthcare system; in this sector, the firm’s expertise is primarily in companies that target healthcare providers as customers, but the firm is also open to considering other areas of the services/IT space. The firm has no fixed requirements for companies or management teams.
If you are interested in more information about this investor and other investors tracked by LSN, please emailĀ mandates@lifesciencenation.com
With LSNās Redefining Early Stage Investments (RESI) conference coming up next Tuesday, I am delighted to announce the good news is RESI seems to have caught fire in the early stage global investor community, with investors making up half of the registered attendees.
The bad news is, when you add that to the fundraising CEOs, RESI Innovation Challenge participants, exhibitors and sponsors, weāve reached capacity at our venue. Weāre therefore unable to take any more registrations.
However, hereās the program guide; we hope that if you didnāt make it to RESI@JPM, you will be able to join us at one of our three events later this year in Houston (April 11th), Toronto (June 23rd), or Boston (September 13th). If youād like to attend a future RESI event, plan early!
Life Science Nationās mission of connecting scientist entrepreneurs with capital gave rise to the Redefining Early Stage Investments (RESI) conference nearly 3 years ago. As we approach our seventh RESI conference, during the highly anticipated JP Morgan week in San Francisco, weāre expecting a record of well over 300 investors representing over 200 different firms in attendance. Figure 1 shows a breakdown of investors by type who will be at RESI San Francisco on January 12, 2016. You can also view the firms represented here.
Venture capital is the most represented investor type, and this includes a growing number of non-traditional venture firms in todayās investment landscape. For instance, the relatively new emergence of the āmicro VCā has more capital flowing into seed and series A stage companies. As shown here, several other investor classes looking for early-stage life science technologies that donāt fall under the venture capital umbrella also have a large presence at the RESI conference. This diversity of investors means that RESI Partnering can provide RESIās great variety of attendees with the opportunity to make a connection with a financing partner thatās the right fit for their round.
Life Science Nationās network of varied investor types will be showcased on an assortment of panels throughout the day. The 16 panels scheduled to take place at RESI San Francisco will cover the full range of companies in the life science space (biotech, medtech, diagnostic and health IT) and the different investor classā tactical guidance for navigating the investment process of their respective niches and outlook on the future of each sector. The LSN research teamās unique perspective on the investment landscape has spurred a new panel that will be held for the first time at RESI San Francisco, Consumer Health āInvesting in Innovative Products for Healthy Living,ā and the return of two panels from former RESI events, Asia-Pacific Investors, āForging Cross-Border Collaborations in Healthcare,ā and Orphan & Rare Disease Investors, āSeeking Returns On Investing In Small Patient Populationsā.
The fundraising process is typically a lengthy one, therefore multiple interactions with prospective investors and strategic partners are essential to a successful campaign. The RESI conference is an ongoing series that provides just that, allowing entrepreneurs to interface with a diverse field of investors, foster existing relationships and make new connections throughout the year, at multiple events. RESI San Francisco is just the first stop for 2016, with additional RESI conferences being held in Houston, Toronto and Boston, later in the year.
This ongoing chain of conferences coupled with the forward-looking investor mandate information used in our partnering platform really makes RESI stand out in terms of the ability to make meaningful connections. To see a demonstration of just how effective the partnering system can be at finding a match, please watch this video.
At LSNās RESI San Francisco Conference next Tuesday, January 12th, the Corporate VC & Strategic Investment panel will focus on how major pharmaceutical companies evaluate and invest in early stage life science companies, both through corporate venture capital arms and internal investment units.
In this panel, corporate VC and major pharmaceutical investors will discuss the types of companies theyāre interested in investing in, and how they structure these opportunities to achieve their strategic aims. Panelists will provide advice on how entrepreneurs can engage with a corporate investor, and what to expect from an investment relationship with a large pharmaceutical company.
Moderated by Edward Hu, CFO & CIO of WuXi AppTec, the audience will hear from:
Carolyn E. Green, Executive Director, Strategic Investments, Worldwide R&D, Pfizer
If youāre a fundraising entrepreneur seeking strategic investments with a major pharmaceutical company, this panel is not one you want to miss. RESI San Francisco is already the largest RESI yet with over 700 attendees. This will be a great opportunity to expand your network in the life science space, so register now before itās too late.
An investment fund offers business training programs for early stage ventures solving global challenges within several fields, including healthcare. The firm typically works with companies who have received less than $1 million in institutional funding and are looking to raise $500K or more in the next 12-18 months. In each program, 12innovative ventures are selected to participate, and among them, two will receive $50,000 investment each through a peer-selection process. The US-based programs are open to companies that are US-based, serving the US market, or with presence in the US.
Within healthcare, the firm is interested in entrepreneurs with solutions that will increase and/or improve access to both healthcare and treatment for low-wealth individuals. Examples may include healthcare IT solutions or innovative medtech and diagnostic tools. The program seeks companies that have developed some sort of traction, either revenue-based or meaningful customer feedback, user acquisition, successful pilots, or strategic partnerships.
The firm looks at experience, competency, and the overall dynamic of management teams. To participate in the business-training programs, the company must have at least one full time team member.
If you are interested in more information about this investor and other investors tracked by LSN, please emailĀ mandates@lifesciencenation.com
